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Abstract
Background: Increasing resistance to clarithromycin and nitroimidazole is the main cause of
failure in the Helicobacter pylori eradication. The ideal retreatment regimen remains unclear,
especially in developing countries, where the infection presents high prevalence and resistance to
antibiotics. The study aimed at determining the efficacy, compliance and adverse effects of a
regimen that included furazolidone, levofloxacin and lansoprazole in patients with persistent
Helicobacter pylori infection, who had failed to respond to at least one prior eradication treatment
regimen.
Methods: This study included 48 patients with peptic ulcer disease. Helicobacter pylori infection was
confirmed by a rapid urease test and histological examination of samples obtained from the antrum
and corpus during endoscopy. The eradication therapy consisted of a 7-day twice daily oral
administration of lansoprazole 30 mg, furazolidone 200 mg and levofloxacin 250 mg. Therapeutic
success was confirmed by a negative rapid urease test, histological examination and 14C- urea
breath test, performed 12 weeks after treatment completion. The Chi-square method was used
for comparisons among eradication rates, previous treatments and previous furazolidone use.
Results: Only one of the 48 patients failed to take all medications, which was due to adverse effects
(vomiting). Per-protocol and intention-to-treat eradication rates were 89% (95% CI- 89%–99%)
and 88% (88–92%), respectively. Mild and moderate adverse effects were reported by 41 patients
(85%). For patients with one previous treatment failure, the eradication rate was 100%. Compared
to furazolidone-naïve patients, eradication rates were lower in those who had failed prior
furazolidone-containing regimen(s) (74% vs. 100%, p = 0.002).
Conclusion: An empiric salvage-regimen including levofloxacin, furazolidone and lansoprazole is
very effective in the eradication of Helicobacter pylori, particularly in patients that have failed one
prior eradication therapy.
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Background
Consensus meetings on H. pylori have advised that the
first-line treatment should be a drug regimen that includes
a PPI and two antimicrobial agents (clarithromycin +
amoxicillin or clarithromycin + metronidazole). The tri-
ple therapy usually results in an eradication rate > 80%. A
high rate of H. pylori primary resistance to nitroimidazole
has been observed in developing countries[1]. Resistance
to clarithromycin and nitroimidazole is responsible for
most H. pylori treatment failures [2,3].
In Brazil, primary bacterial resistance to metronidazole
and clarithromycin is around 56% [4] and 9% [5] respec-
tively. Whereas the first-line eradication regimens fail to
eradicate H. pylori in 5 to 20% of patients in developed
countries[6], this percentage tends to be higher in devel-
oping countries such as Brazil (15–30%) [7-10].
The ideal triple therapy should be effective, safe and low-
cost, which is a difficult goal to achieve [11-13].
Furazolidone is a synthetic nitrofuran derivative with bac-
tericidal or bacteriostatic activity when used against
Gram-positive and Gram-negative bacteria and it is well
absorbed in the intestine with no significant tissue accu-
mulation [14]. It has anti-H. pylori activity and furazo-
lidone-resistant strains appear to be rare or non-existent
in many areas [15], making this drug a potential option in
a rescue regimen for H. pylori eradication.
On the other hand, the efficacy of levofloxacin, a levoro-
tatory isomer of ofloxacin with known activity against H.
pylori [16] has been assessed in several eradication studies
[17,18]. Some recent reports have shown promising
results for levofloxacin-based rescue regimens in the treat-
ment of persistent H. pylori infection. In general, the avail-
able clinical trials have involved small numbers of
patients and have demonstrated variable eradication
rates, ranging from 63% to 100% [19-21]. Therefore, the
aim of the present study was to determine the efficacy,
compliance rate and adverse effects of a regimen includ-
ing furazolidone, levofloxacin and lansoprazole in the
retreatment of H. pylori infection in patients with active or
healed duodenal ulcers, who had failed to respond to at
least one prior regimen for H. pylori eradication.
Methods
This study was a prospective, open-label trial for the treat-
ment of 48 H. Pylori-positive patients with peptic ulcers,
who had previously failed one or more eradication regi-
mens (Table 1). The enrolled patients were selected from
the Gastroenterology Outpatient Clinic of Hospital das
Clinicas, School of Medicine, University of São Paulo
(USP). The study was approved by the Ethics Committee
of the USP and patients who agreed to participate in the
study gave their written informed consent. Bacterial per-
sistence after treatment was confirmed by positive 14C-
urea breath test and rapid urease test and histological
examination using a modified Giemsa staining method.
Gastric mucosa samples were obtained from the antrum
and corpus through upper digestive endoscopy.
Patients who received antisecretory drugs, antibiotic ther-
apy, bismuth compounds or nonsteroidal anti-inflamma-
tory drugs, including low-dose aspirin, up to four weeks
before the start of the study were excluded from it. Previ-
ous gastrointestinal surgery, pregnancy or lactation and
severe comorbidity were the other exclusion criteria.
The patients were submitted to an eradication therapy reg-
imen consisting of a 7-day, twice-daily oral administra-
tion of lansoprazole (30 mg), furazolidone (200 mg) and
levofloxacin (250 mg). Patients were advised not to drink
alcoholic beverages and to avoid foods associated with
potential side effects determined for drugs similar to
monoamine oxidase inhibitors. They were also encour-
aged to follow the prescribed regimen regularly and were
informed about the importance of the adequate use of the
medication for a successful treatment.
No other medication was allowed until the end of the
treatment, when patients were evaluated regarding com-
pliance by counting the remaining tablets. Therapeutic
compliance was defined as the intake of 100% of the pre-
scribed medication. Adverse events were recorded in a
questionnaire, and each clinical adverse effect was care-
fully investigated.
Treatment efficacy was determined by bacterial negativity
in at least two of three diagnostic methods: rapid urease
test, histological examination of gastric antrum and cor-
pus mucosa samples or 14C- urea breath test, performed
12 weeks after completion of the eradication treatment.
Statistical Analysis
Eradication rates were analyzed on an intention-to-treat
and per protocol basis. A confidence interval of 95% was
Table 1: Characteristics of population included in study
age (years) mean 48
median 48
range 20 – 71
sex female 29 (60%)
tobacco use 17 (35%)
ulcer type duodenal 33 (69%)
gastric 11 (23%)
gastric + duodenal 4 (8%)
previous failed treatments 1 28 (58%)
21 3  ( 2 7 % )
3 or more 7 (15%)BMC Gastroenterology 2009, 9:38 http://www.biomedcentral.com/1471-230X/9/38
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calculated for the eradication rate percentiles. The Chi-
square method with Pearson's coefficient was used for
comparisons among the variables, eradication rates,
number of previous treatment, previous use of furazo-
lidone, and statistical significance was set at p < 0.05.
Results
Forty-eight patients, of which 29 (60%) were females,
with a mean age of 48 years (range: 20–71 years) were
included in this study: five presented with active ulcers,
while ulcer scars were observed in 43 of the patients.
Twenty-eight patients had experienced one previous treat-
ment failure (Table 1). The contents of the previous anti-
H. pylori therapies are shown in Table 2.
All but one of the patients took 100% of their prescribed
medication. This patient experienced significant vomiting
and was excluded from the per-protocol analysis. Mild
and moderate adverse effects were reported by 41 patients
(85%). The most frequent complaint was nausea,
reported by 37% of the patients.
Eradication rate was respectively 89% (95% CI: 89–99%)
and 88% (95% CI: 88–92%) in per protocol and inten-
tion-to-treat analyses. Treatment success was related to the
number of previous treatments and to the previous use of
furazolidone (Table 3). All patients previously submitted
to only one treatment achieved successful eradication, but
when 3 or more previous treatment regimens had failed,
the eradication rate decreased to 57% (p = 0.004). All
patients with no previous use of furazolidone achieved H.
pylori eradication.
Discussion
First-line regimens for H. pylori treatment in Brazil usually
include a seven-day course of PPI, clarithromycin and
amoxicillin. The negative impact of clarithromycin resist-
ance on the therapy success for H. pylori eradication is
remarkable, decreasing the eradication rate by more than
20% [22].
International guidelines and the Brazilian consensus rec-
ommend the quadruple therapy with PPI, bismuth subci-
trate, tetracycline, and metronidazole as a second-line
therapy in case of treatment failure [1,23,24]. The disad-
vantages of this bismuth-based quadruple therapy include
the high daily pill count and frequent side effects, which
affect treatment compliance, as well as the high H. pylori
resistance to nitroimidazole compounds observed in our
country.
In the past years, new antibiotics have emerged as poten-
tial agents against antibiotic-resistant H. pylori strains,
such as rifabutin and levofloxacin. Rifabutin provides
eradication rates that range from 79% to 90%, when com-
bined with amoxicillin and PPI [25,26], but it is a very
expensive drug, it is has been associated with myelotoxic-
ity and it is not commercially available in Brazil.
A recent meta-analysis showed that the levofloxacin-based
triple therapy with amoxicillin plus PPI offers a number of
advantages over the bismuth-based quadruple therapy,
such as better overall tolerance and higher efficacy [27].
Furazolidone provides an excellent alternative to the com-
bined therapy for H. pylori eradication [20,28,29], in sub-
stitution to amoxicillin or metronidazole, resulting in
good eradication rates in patients who have had a failed
treatment; however, its use has not become widespread
due to the reported side effects.
The present study confirms the results of Gonzaga et al
study [20], in which eradication rate was 100% (PP anal-
ysis). Unfortunately the number of patients in the study
was very small (12 patients, 2 lost to follow-up). Accord-
ing to this study, the necessary sample size to define the
statistical difference for an eradication rate of 85–90%
would be of at least 40 patients. Our study included 48
patients. The overall treatment success was 89% (42/47)
per protocol and when patients had previously received
only one treatment, eradication success was 100%.
Table 2: Composition of Previous Treatment
previous treatment number of patients
1× OAC 18
OAA' 7
OFT 2
OMC 1
subtotal 28
2× OAA' + OFT 5
OAC + OFT 4
OAA' + OAC 2
OAC + OMC 2
subtotal 13
3 × or more OAA' + OAC + BAFO 2
OAC + OFT + BAFO 2
OMC + OAC + BAMO 1
OAA' + OAC + OFT + BAFO 1
OMC + OAC + OFT + BAFO 1
subtotal 7
total 48
Legend: O: omeprazole, A: amoxicillin, A': azithromycin, F: 
furazolidone, T: tetracycline, M: metronidazole, C: clarithromycin, B: 
subcitrate-bismuth.BMC Gastroenterology 2009, 9:38 http://www.biomedcentral.com/1471-230X/9/38
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Our results are similar to those reported by Nista et al [19]
(PPI+ levofloxacin + tinidazol or amoxicillin) and Sharara
et al [30] (PPI + gatifloxacin and amoxicillin), although
treatment regimens were different. It not advisable to
include nitroimidazole in eradication regimens in Brazil,
as primary resistance to this antibiotic agent is high [1,4,5]
and gatifloxacin is not commercially available in Brazil.
Amoxicillin, an inexpensive drug [31], has been widely
used in first-line and rescue H. pylori eradication regimens.
At least one study in Brazil [32] has shown a very high
resistance to amoxicillin (38%), thus making the inclu-
sion of amoxicillin in retreatment regimens a difficult
decision to be made.
The present study confirms that the rescue therapy efficacy
is directly related to the number of previous treatments. In
patients previously submitted to 3 or more treatments, the
eradication rate was 57% (4 of 7) and among those previ-
ously submitted to one treatment, it was 100% (28 of 28).
Of the 28 patients submitted to one previous treatment,
26 had not received furazolidone. When furazolidone had
been previously included in the treatment regimen, the
eradication success decreased significantly (p = 0.002).
The duration of treatments that include levofloxacin is
another question for debate. Although a seven-day eradi-
cation regimen was effective [28,33] an increase in the
eradication rate was observed when a ten-day regimen was
prescribed. The advantage of a seven-day regimen is the
high adherence, lower cost and fewer adverse events.
Side effects reported with levofloxacin-based regimens
plus amoxicillin are usually rare. It is possible that most of
the side effects reported by our patients were furazo-
lidone-related. Nevertheless, contrary to what usually is
reported by others [34-36], side effects observed in our
study were usually mild or moderate, well tolerated and
did not interfere with patients' compliance.
Empirical rescue regimens used for H. pylori eradication
treatment are a matter of discussion. Although recent
guidelines suggest microbial sensitive tests for H. pylori
retreatment, bacterial cultures are expensive, time-con-
suming and unavailable as routine tests, particularly in
most of the developing countries.
In Brazil, the rescue regimen suggested in this study has a
low cost (US$ 26.00), consisting of only three capsules
bid [37-39], being adequately supplied by the public
health services.
Conclusion
Our results demonstrate that the empiric salvage-regimen
for H. pylori eradication including levofloxacin, furazo-
lidone and PPI is very effective, particularly in patients
previously submitted to a maximum of 2 treatment regi-
mens.
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